Non-activated protein C rescue treatment in Wilms tumour associated hepatic sinusoidal obstructive syndrome

Pediatr Blood Cancer. 2014 May;61(5):940-1. doi: 10.1002/pbc.24859. Epub 2013 Nov 26.

Abstract

Hepatic sinusoidal obstructive syndrome (HSOS) is a frequent complication in patients undergoing haematopoietic stem cell transplant (HSCT), and more rarely, in paediatric patients receiving conventional chemotherapy for solid tumours. Its diagnosis relies on a combination of clinical signs and symptoms such as hepatomegaly, jaundice, weight gain and fluid retention. HSOS treatment is primarily based on supportive care and anti-fibrinolytic agents. Here we report two patients affected by Wilms tumour who developed life-threatening HSOS that failed to respond to conventional treatment. Both patients recovered after receiving aggressive supportive treatment that included administration of non-activated protein C (Ceprotin®--Baxter).

Keywords: Wilms tumour; chemotherapy; support care; veno-occlusive disease.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Hepatic Veno-Occlusive Disease / chemically induced
  • Hepatic Veno-Occlusive Disease / drug therapy*
  • Humans
  • Infant
  • Kidney Neoplasms / drug therapy*
  • Male
  • Protein C / therapeutic use*
  • Treatment Outcome
  • Wilms Tumor / drug therapy*

Substances

  • Fibrinolytic Agents
  • Protein C